Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7767515 | 0.87 | HPGD (0.43) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL6269225 | 0.87 | CA2 (0.41) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL7148753 | 0.87 | CA2 (0.41) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL1308779 | 0.87 | CA2 (0.41) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL13290042 | 0.87 | CA2 (0.41) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL13800900 | 0.87 | CA2 (0.41) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL6241033 | 0.87 | CA2 (0.41) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL15685476 | 0.85 | CA2 (0.61) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL15833416 | 0.85 | CA2 (0.61) | CA2CA1CA9HPGDRXFP1 | |
| SCHEMBL4587323 | 0.85 | CA2 (0.61) | CA2CA1CA9HPGDRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211300-B2 | 4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-06-26 | — | — | US | disclosed |
| WO-2014099941-A1 | 4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178338-A1 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV | FBL, HNRNPLL, SLC28A1 | CA2 4556/4885CA1 4408/4885CA9 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.